Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours. These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More
DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers. CD93 is a novel target downstream of VEGF-A (vascular endothelial growth factor) that has been shown… Read More
An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The researchers found that intravenous (IV) administration of the vaccine… Read More
New research about how cancer-related proteins bind copper ions opens up potential new drug targets to treat cancer. Studies have shown that the level of copper in tumour cells and blood serum from cancer patients is elevated, and the conclusion is that cancer cells need more copper… Read More
Immutep has revealed encouraging initial clinical data from two trials investigating its lead product candidate eftilagimod alpha in non-small-cell lung cancer. Findings from the trials were shared at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022. The INSIGHT-003 trial is evaluating eftilagimod alpha… Read More
Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk… Read More
Scientists have uncovered a critical feature that a promising new class of cancer drugs, known as CELMoDs, needs to be effective. CELMoDs are designed to attack cancer by binding to a regulatory protein called cereblon, which then triggers the degradation of key cancer-driving proteins. In… Read More
An update on the latest oncology developments by DDW Digital Content Editor Diana Spencer The last month has seen huge strides forward in our understanding of cancers, particularly in how they develop resistance to therapies and how we can ‘outsmart’ them using gene editing or different therapeutic pathways, but also… Read More
A team from the University of Geneva (UNIGE) has found a way to overcome chemotherapy resistance in colorectal cancer. The team successfully used a combination of tyrosine kinase inhibitors, opening up new avenues for developing therapies that are more targeted than chemotherapy. Colorectal cancer is… Read More
Cancers can evolve to become more aggressive without relying only on DNA mutations, two major studies have revealed. The research characterises an extra level of control of cancer gene activity within tumours, which the researchers describe as cancer’s ‘dark matter’. The two studies showed how… Read More
A new method to study the proteins released by cells, which could lead to new biomarkers for diseases including cancer, has been developed by scientists at the Francis Crick Institute and Imperial College London. Biomarkers are valuable tools in diagnosing disease or predicting treatment outcomes, but they are… Read More
Scientists have shown how stomach cancers can develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes – raising the possibility of outsmarting cancer by predicting drug resistance in advance. The findings could pave the way for… Read More
Biomedical engineers at Duke University have demonstrated the most effective treatment for pancreatic cancer ever recorded in mouse models. The new treatment completely eliminated tumours in 80% of mice across several model types, including those considered the most difficult to treat. The approach combines traditional… Read More
Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential… Read More
Bertis, a South Korean proteomics-based precision medicine technology company, has established a US-based wholly-owned entity to expand its global presence. The subsidiary, called Bertis Bioscience, aims to establish a San Diego-based CLIA-certified lab facility in early Q4, 2022. It will offer proteomics-based screening and diagnostic tests, as well as an… Read More
Not only is October Breast Cancer Awareness Month but October 21 is Wear it Pink 2022, Breast Cancer Now’s annual fundraising day. While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US1),… Read More
